• 1
    Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899906.
  • 2
    Perticone F, Ceravolo R, Pujia A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 1916.
  • 3
    Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987; 84: 92659.
  • 4
    Drexler H. Nitric oxide and coronary endothelial dysfunction in humans. Cardiovasc Res 1999; 43: 5729.
  • 5
    Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411415.
  • 6
    Lerman A, Edwards BS, Hallett JW, Heublein D, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 9971001.
  • 7
    Zeiher AM, Goebel H, Schächinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. Circulation 1995; 91: 9417.
  • 8
    Arai S, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 7302.
  • 9
    Sakurai T, Yanagisawa M, Takuwat Y et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348: 7325.
  • 10
    Boulanger C, Luscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85: 58790.
  • 11
    Clozel M, Gray GA, Breu V, Löffler BM, Osterwalder R. The endothelin ETB receptor mediates both vasodilatation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992; 186: 86773.
  • 12
    Böhm F, Ahlborg G, Pernow J. Endothelin-1 inhibits endothelium-dependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. Clin Sci (Lond) 2002; 102: 3217.
  • 13
    Dagassan P, Breu V, Clozel M et al. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol 1996; 27: 14753.
  • 14
    Pernow J, Böhm F, Johansson BL, Hedin U, Ryden L. Enhanced vasoconstrictor response to endothelin-B-receptor stimulation in patients with atherosclerosis. J Cardiovasc Pharmacol 2000; 36: S41820.
  • 15
    Böhm F, Ahlborg G, Johansson BL, Hansson LO, Pernow J. Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 6749.
  • 16
    Mancini GB. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations. Clin Invest Med 2000; 23: 14461.
  • 17
    Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 16875.
  • 18
    Dohi Y, Hahn AW, Boulanger CM, Buhler FR, Luscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992; 19: 1317.
  • 19
    D'Uscio LV, Shaw S, Barton M, Luscher TF. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function. Hypertension 1998; 31: 130510.
  • 20
    Hemsén A, Larsson O, Lundberg JM. Characteristics of endothelin A and B binding sites and their vascular effects in pig peripheral tissues. Eur J Pharmacol 1991; 208: 31322.
  • 21
    Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998; 35 (Pt 6): 74553.
  • 22
    Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med 2003; 163: 115564.
  • 23
    MacMahon S, Sharpe N, Gamble G et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. Part-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 2000; 36: 43843.
  • 24
    Ghiadoni L, Virdis A, Magagna A, Taddei S, Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35: 5016.
  • 25
    Ross R. Atherosclerosis: current understanding of mechanisms and future strategies in therapy. Transplant Proc 1993; 25: 20413.
  • 26
    Barton M, Haudenschild CC, D'Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 1998; 95: 1436772.
  • 27
    Verma S, Lovren F, Dumont AS et al. Endothelin receptor blockade improves endothelial function in human internal mammary arteries. Cardiovasc Res 2001; 49: 14651.
  • 28
    Dashwood MR, Tsui JC. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis 2002; 160: 297304.
  • 29
    Sebestjen M, Zegura B, Keber I. Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia. J Intern Med 2002; 251: 7785.
  • 30
    Mancini GB, Henry GC, Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 25865.
  • 31
    Prasad A, Husain S, Quyyumi AA. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin. J Am Coll Cardiol 1999; 33: 796804.
  • 32
    Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002; 62: 26584.
  • 33
    Sorensen KE, Kristensen IB, Celermajer DS. Atherosclerosis in the human brachial artery. J Am Coll Cardiol 1997; 29: 318322.
  • 34
    Anderson TJ, Uehata A, Gerhard MD et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 123541.
  • 35
    Cardillo C, Campia U, Kilcoyne CM, Bryant MB, Panza JA. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation 2002; 105: 4526.